Hi Michael, I think this would be a great call to reschedule. I know you do the best you can, but we do to. With so little notice of the topic, many members may have conflicts. Also it is necessary to have time to review documents ahead of time. You and Sophia put time into preparing the documents (tx you), but we should be allowed to have time to review them... and we all have very busy lives so a few days, at a minimum, is key. Have you circulated the draft? On this important, well-discussed and not-in-agreement topic, I strongly recommend /and request /a bump of a week or to to give everyone a chance to review materials ahead of time and prepare based on these materials. But a day's notice on this topic -- at a height of the US business day time when people already many conflicts with this timing -- on this topic, with virtually no notice, is hardly fair timing. Best, Kathy On 1/31/2018 12:58 AM, Michael Flemming wrote:
Dear All,
Please note that this week we have a call scheduled for WT2. I know that a lot of individuals are traveling for a number of sessions and events being held throughout this week. Unfortunately, we are unable to reschedule the 1 February 2018 15 UTC call, so I invite individuals to comment and provide feedback over the mailing list. The topic for this week will be *Closed Generics*.
As Sophia and I have highlighted in our emails over the last several weeks, we have been putting together documents that summarize, analyze, and offer paths forward for our topics in WT2. Already we have looked at the Registry Agreement, Registrant Protections, Reserved Names, and the Applicant Terms and Conditions. Documents have been circulated and shared with the group, but we have had very little feedback outside of our biweekly calls. I highly encourage participants to provide feedback on what we have highlighted and are proposing in these documents. The goal for these documents is to present to the overall WG what we are recommending as WT2.
I hope those of you that can join us will do so this week to engage in our discussion on Closed Generics.
Sincerely,
Michael Flemming & Sophia Feng WT2 Co-Chairs
_______________________________________________ Gnso-newgtld-wg-wt2 mailing list Gnso-newgtld-wg-wt2@icann.org https://mm.icann.org/mailman/listinfo/gnso-newgtld-wg-wt2